The expression of gonadotropin-releasing hormone (GNRH) receptor (GNRHR) and the direct role of GNRH1 on corpora lutea function were studied in Mediterranean buffalo during diestrus. Immunohistochemistry evidenced at early, mid, and late luteal stages the presence of GNRHR only in large luteal cells and GNRH1 in both small and large luteal cells. Real-time PCR revealed GNRHR and GNRH1 mRNA at the three luteal stages, with lowest values in late corpora lutea. In vitro corpora lutea progesterone production was greater in mid stages and lesser in late luteal phases, whereas prostaglandin F2 alpha (PGF2alpha) increased from early to late stages, and PGE2 was greater in the earlier-luteal phase. Cyclooxygenase 1 (prostaglandin-endoperoxide synthase 1; PTGS1) activity did not change during diestrus, whereas PTGS2 increased from early to late stages, and PGE2-9-ketoreductase (PGE2-9-K) was greater in late corpora lutea. PTGS1 activity was greater than PTGS2 in early corpora lutea and lesser in late luteal phase. In corpora lutea cultured in vitro, the GNRH1 analog (buserelin) reduced progesterone secretion and increased PGF2alpha secretion as well as PTGS2 and PGE2-9-K activities at mid and late stages. PGE2 release and PTGS1 activity were increased by buserelin only in late corpora lutea. These results suggest that GNRH is expressed in all luteal cells of buffalo, whereas GNRHR is only expressed in large luteal phase. Additionally, GNRH directly down-regulates corpora lutea progesterone release, with the concomitant increases of PGF2al-pha production and PTGS2 and PGE2-9-K enzymatic activities.
INTRODUCTION
Gonadotropin-releasing hormone (GNRH) influences reproductive processes mainly by regulating pituitary gonadotropin synthesis and release, which in turn modulate steroidogenesis and gametogenesis [1] . Even if the hypothalamus and pituitary are, respectively, the principal source of and target site for GNRH, several studies have reported an extrahypothalamic origin of GNRH, as well as an extrapituitary presence of GNRH receptor (GNRHR) in numerous peripheral tissues, including reproductive organs such as testis, prostate, ovary, oviduct, placenta, and mammary gland [2] .
There are currently 15 identified naturally occurring GNRH structural variants across the vertebrate species [3] . However, it is evident that at least three forms of GNRH are present in the majority of the vertebrate species studied: hypothalamic GNRH (GNRH1), mid brain GNRH (GNRH2), and telencephalic GNRH (GNRH3) [4, 5] .
Although three types of GNRHR have been identified thus far, mammals have only two types of receptors: GNRHR and GNRHR2 [6] . All known GNRHRs are transmembrane G protein-coupled receptors that produce their effects by activating phospholipase A2 (PLA2), PLC, PLD, or adenylate cyclase (AC) cell signaling pathways [6] . Phospholipase activation may generate arachidonic acid (AA), which is converted into prostaglandins (PGs) by action of the cyclooxygenases (prostaglandin-endoperoxide synthase; PTGS) 1 and 2 as well as by that of other PG synthase enzyme types [7] . In particular, the biosynthesis of PGF2a is peculiar because it derives from three different pathways catalyzed by corresponding ketoreductases using PGH2, PGD2, or PGE2 as substrates [8] .
GNRH exerts both inhibitory and stimulatory effects in the gonads, with either down-or up-regulation of the ovarian cellular steroid production [2, 5] . In particular, GNRHR is constitutively expressed in rabbit corpora lutea (CL) independently of luteal stage, whereas GNRH directly downregulates CL progesterone production via PGF2a at mid and late luteal stages of pseudopregnancy [9] .
To date, no studies have addressed the direct effects of GNRH in buffalo, and thus the objectives of the present study were to examine the in vitro modulatory effects of GNRH on buffalo CL during early, mid, and late luteal stages of diestrus. To this end, experiments were devised to elucidate the presence of GNRH1, GNRHR, PTGS1, PTGS2, and PGE2-9-ketoreductase (PGE2-9-K), as well as the effects of GNRH1 on the production of progesterone, PGE2, and PGF2a, and on the activities of PTGS1, PTGS2, and PGE2-9-K. and reagent for isolation and purification of total RNA (TRIzol), Taq DNA polymerase (Platinum), 103 PCR Buffer, 50 mM MgCl 2 , RNase-free tubes, RNase-free water, and deoxynucleotide triphosphates were also obtained. Primers for mRNAs of GNRH1, GNRHR, PTGS1, PTGS2, PGE2-9-K, and 18S rRNA and corresponding competimers (QuantumRNA 18S Internal Standards) were also acquired from Invitrogen. Nucleospin Extract II kit was purchased from Macherey Nagel Inc.
Titrated progesterone, PGF2a, PGE2, and AA were purchased from Amersham Biosciences Ltd., whereas nonradioactive hormones and specific antisera came from Sigma-Aldrich.
Mouse monoclonal anti-GNRHR and anti-GNRH1 primary antibodies were obtained from Thermo Scientific and Chemicon International, respectively. Rabbit polyclonal anti-PTGS1, and goat polyclonal anti-PTGS2 and anti-PGE2-9-K primary antibodies were purchased from Abcam. Biotin rabbit antigoat immunoglobulin G (IgG) and biotin goat anti-mouse and anti-rabbit IgG secondary antibodies were obtained from Santa Cruz Biotechnology. Avidinbiotin complex (ABC Kit); chromogen 3,3 0 -diaminobenzidine tetrachloride (DAB); and rabbit, mouse and goat IgG were purchased from Vector Laboratories.
The kit for protein assay was purchased from Bio-Rad Laboratories. Medium 199 and Earle Balanced Salt Solution were from GIBCO. HEPES, bovine serum albumin (BSA), buserelin, NS-398, and acetyl salicylic acid were purchased from Sigma, whereas all other pure grade chemicals and reagents were obtained locally.
Animal Tissue Collection
Ovaries from 18 clinically healthy nonpregnant Mediterranean buffaloes (Bubalus bubalis) were collected at the abattoirs. The animals had undergone a general veterinary assessment of their reproductive tract and ovaries before slaughter by rectal palpation and ovarian ultrasonography examination to exclude any apparent abnormalities and early pregnancy. Ovarian scanning was performed using a portable MicroMaxx SonoSite equipped with a 10-MHz linear transducer adapted for transrectal examination in large domestic animals. Buffalo whole genitalia, containing ovaries with CL at different development stages, were collected immediately after slaughter, during the reproductive period (summer-autumn). The CL, promptly removed, were dissected and classified into early (3-5 days, numerous blood vessels and ovulatory depression), mid (6-15 days, clear neck with ovarian stroma and brownish appearance of surface after decapsulation), and late (16-20 days, fewer blood vessels associated with loss of brownish pigmentation and appearance of the whitish color in CL), based on the method previously reported [10] . Plasma samples were collected by jugulation to confirm the diestrous stages of CL used.
Corpora lutea were then washed with saline and immediately processed for in vitro experiments or frozen at À808C after rinsing with RNase-free PBS, for later evaluation of gene expression. For the immunohistochemical studies, CL for each luteal stage were fixed by immersion in 4% (w/v) formaldehyde in PBS (pH 7.4) for 24 h at room temperature, and subsequently processed for embedding in paraffin following routine tissue preparation procedures. The pituitary gland of a female buffalo was taken and processed as positive control tissue for immunohistochemical analysis.
Immunohistochemistry
Tissue sections were deparaffinized in xylene, rehydrated through graded ethanol, and rinsed in distilled water. The CL sections of each luteal stage were stained with hematoxylin and eosin to evaluate morphological features. For GNRHR and PGE2-9-K detection, sections were submitted to antigen retrieval by microwaving in citrate buffer solution (10 mM, pH 6) at 700 W for 10 min. The slides were cooled at room temperature. After rinsing with Tris-buffered saline (TBS), the specimens were dipped in 3% H 2 O 2 (v/v) in methanol for 1 h to quench the endogenous peroxidase activity and were rinsed in TBS. Background labeling was prevented by incubating the sections with normal goat serum (for GNRH1, GNRHR, and PTGS1) and normal rabbit serum (for PTGS2 and PGE2-9-K), diluted 1:10, for 30 min at room temperature. Tissue sections were then incubated for 1 h at 378C and then overnight at 48C in a moist chamber with the following primary antibodies diluted in TBS containing 0.1% BSA: goat polyclonal anti-GNRHR, raised against 18 C-terminal residues (1:200), mouse monoclonal anti-GNRH1 (1:200), rabbit polyclonal anti-PTGS1 (1:50), goat polyclonal anti-PTGS2 (1:50), and goat polyclonal anti-PGE2-9-K (CBR1; 1:500) [11] . The next day, the slides were rinsed in TBS three times, 5 min each time, treated again with normal serum, and then incubated with biotin rabbit anti-goat (for PTGS2 and PGE2-9-K), biotin goat anti-mouse (for GNRH1 and GNRHR), and biotin goat anti-rabbit (for PTGS1) secondary antibodies diluted 1:200 in TBS for 30 min at room temperature. After TBS washes, the slides were exposed to ABC for 30 min and rinsed again with TBS. The peroxidase activity sites were visualized using the DAB kit as chromogen; then, the specimens were rinsed twice with distilled water, 5 min each time, in some cases counterstained with hematoxylin, washed in running tap water and, finally dehydrated by being passed through graded ethanol (70%, 95%, and 100% [v/v]), cleared in xylene, and mounted with medium for light microscopy. Tissue sections in which the primary antibody was omitted or substituted with rabbit, mouse, or goat IgG were used as negative controls of nonspecific staining. The pituitary tissue of a female buffalo was included as a positive control to verify whether the antibody anti-GNRHR recognizes the receptor in this species. The intensity of immunostaining for all antibodies was assessed and compared microdensitometrically as previously described [9] . The image analysis system (IAAS 2000 image analyzer; Delta Sistemi) was calibrated by taking the background developed in sections incubated with antiserum as ''zero'' and a conventional value of maximum intensity of staining as ''100.'' Data were expressed in arbitrary units.
GNRH1, GNRHR, PTGS1, PTGS2, and PGE2-9-K Multiplex RT-PCR
Total RNA was extracted from CL of six buffaloes for each luteal stage as previously described [12] . Five micrograms of total RNA was reverse transcribed in 20 ll of SuperScript III Reverse Transcriptase cDNA synthesis mix using random hexamer according to the protocol provided by the manufacturer. Genomic DNA contamination was checked by developing the PCR without reverse transcriptase. Multiplex PCR amplification was conducted as previously described [12] using 1 ll of luteal cDNA as template for targets (Table 1 ) and 18S primers. Cycling conditions consisted of an initial denaturizing cycle at 948C for 75 sec, followed by 35 cycles for each target gene at 948C for 15 sec, 608C for 30 sec, 728C for 45 sec, and a final extension step at 728C for 10 min. Within each experiment and for each gene analyzed, the complete set of samples was processed in parallel in a single PCR, using aliquots of the same PCR master mix. The amplified PCR-generated products (20 ll of 25-ll total reaction volume) were analyzed by electrophoresis on 2% agarose gel using ethidium bromide staining. Analysis of amplification products was conducted as reported previously [12] . The amplified products, collected from agarose gel after electrophoresis, were purified with the Nucleospin Extract II kit and their identity confirmed by DNA sequencing with Sanger method.
In Vitro Experiments
A method previously reported was used for the in vitro study [13] . Early, mid, and late CL were minced and an approximately 300-mg aliquot from each CL was randomly distributed (one CL aliquot per well) into incubation wells (Becton Dickinson Co.) in 1 ml of culture medium 199 with Earle Balanced Salt Solution, containing 2.2 mg/ml sodium bicarbonate, 2.3 mg/ml HEPES, and 3% BSA (w/v), referred to here as M199. Each set of incubation wells was divided into two experimental groups, each formed of 10 wells as follows: 1) medium alone as control or 2) GNRH1 agonist (buserelin; 200 nM). The culture plates were incubated at 378C in air with 5% CO 2 . The media of each well were collected after 4 h of incubation and stored immediately at À208C for later determination of progesterone, PGF2a, and PGE2. Preliminary evidence led to our choosing the incubation conditions and the minimum effective dose for buserelin used in the present in vitro study (Fig. 1) .
Hormone Determination
Progesterone, PGF2a, and PGE2 were determined following the radioimmunoassay protocols previously reported [13] . Plasma progesterone concentrations were used to confirm the diestrous stages of CL used. Intraassay and interassay coefficients of variation and minimum detectable dose were, respectively: progesterone, 6%, 10%, and 11 pg; PGF2a, 11%, 14%, and 21 pg; and PGE 2 , 8%, 13%, and 17 pg.
Enzyme Activity Determination
PTGS1 and PTGS2 activities were determined by measuring the disappearance of the radiolabeled substrate [ 3 H]AA using a method previously reported [14] . Selective PTGS2 inhibitor (NS-398; 1 lM) and nonselective PTGS inhibitor (acetylsalicylic acid; 1 mM) were used. For each sample, PTGS1 activity was determined by calculating the rate of loss of [ 
Statistical Analysis
Data on gene and protein expressions, hormone levels, and enzyme activities were examined by Levene test and ANOVA followed by Student-NewmanKeuls t-test. Differences were considered significant at P , 0.01.
RESULTS

Progesterone Plasma Levels
The evaluation of progesterone plasma levels confirmed the CL stages: early (n ¼ 6), 0.23 6 0.08 ng/ml; mid (n ¼ 6), 3.74 6 0.62 ng/ml; and late (n ¼ 6), 1.94 6 0.49 ng/ml. Plasma levels were greater (P , 0.01) in mid phase and lesser (P , 0.01) in early phase.
GNRH1, GNRHR, PTGS1, PTGS2, and PGE2-9-K Immunolocalization
The histological sections of CL stained with hematoxylin and eosin evidenced the presence of both large and small luteal cells (data not shown).
GNRH1 was evident in the cytoplasm of all luteal cells during early and mid stages (Fig. 2, A and B) and it decreased (P , 0.01; Fig. 3 ) in late CL (Fig. 2C) . Intense immunostaining was also observed in the cytoplasm of blood vessel cellular components (endothelial, smooth muscular, and stromal cells; Fig. 2 , B and C). Weak immunopositivity for GNRHR was detected in the cytoplasm of large luteal cells (LLCs) during early and mid stages (Fig. 2, D and E) ; this reactivity increased (P , 0.01; Fig. 3 ) in late CL (Fig. 2F) . The small luteal cells (SLCs) were always negative (Fig. 2, D-F) .
Strong positive immune reaction for PTGS1 was localized in the cytoplasm of SLCs in the CL of all stages examined (Fig. 2 , G-I), whereas LLCs were negative (Fig. 2, G-I) . The immunodensity did not change during the CL stages (Fig. 3) . PTGS2 immunostaining was evidenced intensely in the cytoplasm of LLCs during all stages examined (Fig. 2, J-L) , whereas SLCs were negative (Fig. 2, J-L) . The immunodensity was greater (P , 0.01) in late CL (Fig. 3) . Immunosignals for PGE2-9-K were observed in the cytoplasm of luteal cells (Fig.  2, M-O) . Immunodensity was greater (P , 0.01) in late CL (Fig. 3) .
The control staining procedure failed to disclose appreciable reactivity at any of the abovementioned sites (data not shown).
The cytoplasm of several pituitary cells exhibited intense immunostaining (data not shown).
Gene Expression of GNRH1, GNRHR, PTGS1, PTGS2, and PGE2-9-K PTGS2, as evidenced by the relative abundance of mRNA, was less (P , 0.01) in the late luteal phase (Fig. 4) . PTGS1 transcript levels were lower (P , 0.01) and PTGS2 transcript levels higher (P , 0.01) in late CL (Fig. 4) . PGE2-9-K transcripts did not modify during the three luteal stages (Fig.  4) .
In Vitro Incubation
Progesterone release was greater (P , 0.01) in mid phase and lesser (P , 0.01) in early phase; PGF2a synthesis increased (P , 0.01) from early to late stage; and PGE2 was greater (P , 0.01) during early stage (Fig. 5 ). Buserelin reduced (P , 0.01) progesterone and increased (P , 0.01) PGF2a secretions during mid and late stages, whereas PGE2 was increased (P , 0.01) only in late CL (Fig. 5 ).
Enzymatic Activities
PTGS1 activity values were greater (P , 0.01) than PTGS2 in early and mid CL and lower (P , 0.01) in late CL (Fig. 6 ). PTGS1 activity did not change from early to late stages in regressed CL (Fig. 6 ). PTGS2 activity increased (P , 0.01) from early to late stage (Fig. 6 ). PGE2-9-K was greater (P , 0.01) in late CL with respect to other CL types (Fig. 6 ). Buserelin enhanced (P , 0.01) PTGS2 and PGE2-9-K activities in mid and late CL, whereas PTGS1 was increased (P , 0.01) only during late stage (Fig. 6) . 
DIRECT GNRH1 EFFECTS ON BUFFALO CORPORA LUTEA
DISCUSSION
This study reports for the first time the occurrence of a GNRH/GNRHR system in buffalo CL during diestrus, suggesting that GNRH1 and GNRHR are constitutively expressed and that GNRH1 has a role in modulating the endocrine function of CL in this species.
The presence of GNRHR in the ovary, through ligandspecific binding sites, was initially seen in rat granulosa and luteal cells [15] [16] [17] . Afterward, the presence of GNRHR mRNA was also evidenced in human granulosa luteal cells [18] and in cattle follicles and CL [19] . GNRHR was measurable in varying amounts in CL at different stages; in particular, it was detectable in stage III luteal tissues [19] . Recently, the presence of GNRHR at both transcript and protein levels was detected in CL of pseudopregnant rabbits [9] . Apparently, both mRNA and protein abundances did not change at different luteal stages. Positive staining for GNRHR was clearly evident in the cytoplasm of luteal cells during all stages of pseudopregnancy [9] . In the present study, GNRHR immunopresence and gene expression were evident during all luteal stages. In particular, GNRHR immunosignals were detected only in the cytoplasm of LLC, with an increase in late CL. On the other hand, our histological sections do not exclude the localization of GNRHR on cytoplasmatic membrane also, as reported in other species [2] . Conversely, GNRHR mRNA values were lower in late CL.
In previous studies, GNRH1 was present in the ovary of rat [20, 21] , monkey [22] , human [23] , hamster [24] , and rabbit [9] . The last authors evidenced the presence of GNRH1 in the cytoplasm of luteal cells during early, mid, and late stages of pseudopregnant rabbit CL. Present results demonstrated a clear immunopresence of GNRH1 in both SLCs and LLCs. An interesting result was the localization of GNRH1 in the cellular components of blood vessels, as previously reported in the pseudopregnant rabbit ovary [9] . This finding, together with the presence of GNRHR in LLCs, supports the existence of cross talking between luteal and blood vessel cells, but at present its physiological role is still uncertain. However, given the strict relationship between blood flow and luteal steroidogenesis [25] , this infers the GNRH1 extends its role by locally modulating blood supply.
GNRH exerts various effects in the gonads [2] , causing either inhibitory effects [9, 26, 27] , stimulatory effects [28] [29] [30] , or neither kind of effect [28, 31, 32] on ovarian cellular steroid output in several mammalian species. Results from the present study support the idea that GNRH1 has a direct role in the down-regulation of buffalo CL progesterone production. In fact, in vitro experiments showed that buserelin reduced progesterone production by cultured CL taken at mid and late luteal stages, whereas the effects of this GNRH1 agonist were not found in early CL. These results are in agreement with previous studies performed in cattle [26, 27] . Those authors reported that two GNRH antagonists, buserelin and deslorelin, have in vivo and in vitro inhibitory effects on progesterone release. Compared with native GNRH, GNRH agonists have a higher affinity for cognate receptors and a longer half-life in circulation [27] . These two distinguishing features suggest that GNRH agonists have considerable potential for fertility applications [27] . With regard to basal production of progesterone in the present study, in vitro data indicate that the mid-luteal phase CL (6-15 days) synthesize the greatest amount of this steroid, in agreement with previous in vivo studies reporting that the buffalo showed the maximal plasma concentrations of this steroid between Days 6 and 16 of the estrous cycle [33, 34] .
PTGS1 and PTGS2, the enzymes involved in PG synthesis, have a pivotal role in CL lifespan regulation [35] . In this context, Arosh et al. [36] reported that PTGS2 is highly modulated, whereas PTGS1 is expressed at a constant level during the cattle CL lifespan. These authors also found that cellular localization of PTGS2 preferentially occurs in LLCs, whereas they did not report any data on PTGS1 immunohistochemistry [36] . More recently, in our laboratories we demonstrated [37] the immunopresence of PTGS1 in the cytoplasm of SLCs in growing CL of cattle; conversely, PTGS2 immunolocalization was evidenced in LLCs, a finding also reported by Arosh et al. [36] . These studies are in agreement with the present results indicating PTGS1 immunosignals in SLCs and PTGS2 in LLCs in diestrous buffalo CL. PTGS1 mRNA was lesser in the late luteal phase, whereas PTGS2 mRNA was greatest in the same CL. Although PTGS2 is considered an inducible isoenzyme, some authors have suggested that it is constitutively expressed in reproductive [11, 38, 39] and nonreproductive [40, 41] tissues. Immunohistochemical and gene expression results from the present study agree with these studies, suggesting the presence of a constitutive PTGS2 isoform in buffalo CL. PTGS1 enzymatic activity was constant during all three luteal stages. Conversely, PTGS2 activity increased from early to late stages, supporting the involvement of this enzyme in buffalo CL luteolysis. Recent studies with the CL of cattle demonstrated that PTGS2 had an enzymatic activity similar to that of buffalo, whereas PTGS1 was greater in the late luteal phase [37] . These data suggest that there are similar and different mechanisms that regulate CL in cattle and buffalo. PGE2-9-K immunostaining was evidenced in the cytoplasm of LLCs and SLCs of all of the stages considered, with the highest immunopresence in late CL. Conversely, the mRNA was expressed in all CL. The PGE2-9-K enzymatic activity was greater in the late luteal phase. To date, nothing has been reported in the literature about the immunopresence of PGE2-9-K in buffalo CL. The above findings suggest that PTGS2 and DIRECT GNRH1 EFFECTS ON BUFFALO CORPORA LUTEA PGE2-9-K, expressed in LLCs, play a role in the luteolysis processes through a paracrine mechanism involving PGF2a synthesis by LLCs and, in turn, the down-regulation of progesterone production by SLCs induced by this PG, as previously reported also in cattle [36] .
Considering that PTGS1 immunoreactivity is seen in SLCs only, that its highest activity occurs in the late stage, and that PGE2-9-K occurs in SLCs, an intriguing idea comes to mind: it is possible that late-stage CL produce high levels of PGF2a that, with a paracrine loop, down-regulate SLC progesterone synthesis. In this context, some authors have suggested that extraluteal production of PGF2a initiates the inhibition of progesterone production accompanying functional luteolysis, whereas the intraluteal PGF2a production contributes to structural luteolysis by the activation of an autoamplification loop in CL of pig, sheep, cow, and rabbit [14, 36, [42] [43] [44] .
Data from the present study on the in vitro effects of buserelin showed that this GNRH1 agonist induced an increase of PGF2a with a concomitant decrease in progesterone release by mid and late CL. Buserelin affected enzyme activities as well; indeed, PTGS1 and PGE-2-9-K were greater during mid and late stages, whereas PTGS activity was enhanced in late CL only. In agreement with the present findings, Naor et al. [45] hypothesized a novel GNRH signaling pathway mediated by PGF2a, which acts through an autocrine/paracrine modality.
These authors reported that in the gonadotrope cell line LbT2, GNRH produced a marked time-dependent induction of PTGS2 expression and an increase of PGE2 and PGF2a production. More recently, it was suggested that the GNRH1 effects on the decrease of rabbit CL progesterone production are mediated by the activation of the PTGS2/PGF2a pathway [9] .
The present in vitro data showed that buserelin did not affect hormone production and enzyme activities in early CL; thus, in these CL there was a refractoriness to GNRH. In domestic species and primates, luteal regression is initiated by PGF2a, but during the early stages of the reproductive cycle, the CL are refractory to this PG [46] . This physiological mechanism protects the growing CL from functional luteolysis until the CL shift from refractoriness to responsiveness to exogenous PGF2a and acquire luteolytic competence [47] . In particular, luteolysis cannot be initiated before Day 5 of the estrous cycle in the cow [48, 49] , Day 8 in the marmoset monkey [50] , Day 4 in rat [51] , and Day 6 in rabbit [52] . In vitro data on the effectiveness of buserelin at the early luteal stage suggest that this anti-luteolytic-protecting mechanism could also include the GNRH/GNRHR system in buffalo CL.
In summary, GNRH1 has an autocrine (by LLCs) and a paracrine (by SLCs and/or blood vessel cells) action (even if the endocrine way cannot be excluded), directly down- regulating progesterone production in buffalo CL with a cellular mechanism, as reported in Figure 7 (see Supplemental Movie S1, available online at www.biolreprod.org). GNRH1 couples its cognate receptor in LLCs, activating PTGS2 and PGE2-9-K enzymes, with a consequent increase in PGF2a production; this PG induces, via a paracrine mechanism, a decrease in progesterone synthesis by SLCs. However, although the present data shed new light on GNRH1 physiological mechanisms regulating luteal activity of Mediterranean buffalo, further studies are needed to better understand the fine-tuning of the GNRH/GNRHR system that controls the CL lifespan of this species. This knowledge could allow us to improve the reproductive efficiency of the Mediterranean buffalo during the nonreproductive season, so that subsequent milk supply coincides with the peak time of demand for the production of mozzarella cheese [53] .
